$27.10
0.11% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US14167L1035
Symbol
CDNA
Sector
Industry

CareDx, Inc. Stock price

$27.10
+2.09 8.36% 1M
+15.38 131.23% 6M
+15.10 125.83% YTD
+18.29 207.61% 1Y
-48.25 64.03% 3Y
+5.40 24.88% 5Y
+16.26 150.00% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.03 0.11%
ISIN
US14167L1035
Symbol
CDNA
Sector
Industry

Key metrics

Market capitalization $1.43b
Enterprise Value $1.23b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.15
P/S ratio (TTM) P/S ratio 4.81
P/B ratio (TTM) P/B ratio 5.39
Revenue growth (TTM) Revenue growth -3.95%
Revenue (TTM) Revenue $297.08m
EBIT (operating result TTM) EBIT $-76.01m
Free Cash Flow (TTM) Free Cash Flow $-21.41m
Cash position $228.87m
EPS (TTM) EPS $-2.99
P/E forward negative
P/S forward 4.39
EV/Sales forward 3.79
Short interest 8.06%
Show more

Is CareDx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

CareDx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a CareDx, Inc. forecast:

5x Buy
56%
3x Hold
33%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a CareDx, Inc. forecast:

Buy
56%
Hold
33%
Sell
11%

Financial data from CareDx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
297 297
4% 4%
100%
- Direct Costs 107 107
5% 5%
36%
191 191
3% 3%
64%
- Selling and Administrative Expenses 173 173
2% 2%
58%
- Research and Development Expense 76 76
16% 16%
25%
-58 -58
17% 17%
-19%
- Depreciation and Amortization 18 18
1% 1%
6%
EBIT (Operating Income) EBIT -76 -76
13% 13%
-26%
Net Profit -160 -160
90% 90%
-54%

In millions USD.

Don't miss a Thing! We will send you all news about CareDx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CareDx, Inc. Stock News

Neutral
Business Wire
22 days ago
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ – today announced that the Centers for Medicare and Medicaid Services (CMS) has announced its plan to retire a draft LCD that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection. Combined with the February 2024 removal of restrictive language in the accom...
Neutral
Seeking Alpha
about one month ago
CareDx, Inc. (NASDAQ:CDNA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and CEO Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Alex Johnson - President, Patient and Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Kayla Hostetler - Jefferies P...
Neutral
PRNewsWire
about 2 months ago
NEW YORK , July 16, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating CareDx, Inc. (NASDAQ: CDNA) on behalf of the company's shareholders.  The investigation seeks to determine whether CareDx's directors breached their fiduciary duties in connection with recent corporate actions.
More CareDx, Inc. News

Company Profile

CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Head office United States
CEO John Hanna
Employees 643
Founded 1998
Website www.caredx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today